vatalanib has been researched along with Leiomyosarcoma in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bold, G; Breier, G; Buchdunger, E; Diermeier-Daucher, S; Drexler, HC; Gaumann, AK; Lang, SA; Stoeltzing, O; Wood, J | 1 |
1 other study(ies) available for vatalanib and Leiomyosarcoma
| Article | Year |
|---|---|
The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib®).
Topics: Angiogenesis Inhibitors; Becaplermin; Cell Line, Tumor; Cell Movement; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Leiomyosarcoma; Neovascularization, Pathologic; Phthalazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pyridines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2014 |